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Summary- Blood CrAg testing should be considered in all severely immunocompromised HIV-
infected individuals who are hospitalized with suspected meningitis. Fluconazole monotherapy is 
inadequate for individuals with neurologic symptomatic cryptococcal antigenemia.  
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Abstract:  
Background: Individuals with cryptococcal antigenemia are at high risk of developing cryptococcal 
meningitis if untreated.  The progression and timing from asymptomatic infection to cryptococcal 
meningitis is unclear. We describe a sub-population of individuals with neurologic symptomatic 
cryptococcal antigenemia, but negative CSF studies.  
Methods: We evaluated 1201 HIV-seropositive individuals hospitalized with suspected meningitis in 
Kampala and Mbarara, Uganda. Baseline characteristics and clinical outcomes of participants with 
CNS-symptomatic cryptococcal antigenemia and negative CSF CrAg were compared to participants 
with confirmed CSF CrAg+ cryptococcal meningitis. Additional CSF testing included microscopy, 
fungal culture, bacterial culture, TB culture, multiplex FilmArray PCR (Biofire), and Xpert MTB/Rif 
(Cepheid).  
Results: We found 56% (671/1201) of participants had confirmed CSF CrAg+ cryptococcal 
meningitis, and 4% (54/1201) had neurologic symptomatic cryptococcal antigenemia with negative 
CSF CrAg. Of those with negative CSF CrAg, 9% (5/54) had Cryptococcus isolated on CSF culture 
(n=3) or PCR (n=2), and 11% (6/54) had confirmed tuberculous meningitis. CSF CrAg-negative 
patients had lower proportions with CSF pleocytosis (16% vs 26% with >=5 white cells/mcL) and 
CSF opening pressure >200mmH2O (16% vs 71%) compared with CSF CrAg+. No cases of bacterial 
or viral meningitis were detected by CSF PCR or culture.  In-hospital mortality was similar between 
symptomatic cryptococcal antigenemia (32%) and cryptococcal meningitis (31%) (P=.91).  
Conclusions: Cryptococcal antigenemia with meningitis symptoms was the third most common 
meningitis etiology. We postulate this is early cryptococcal meningoencephalitis. Fluconazole 
monotherapy was suboptimal, despite Cryptococcus-negative CSF. Further studies are warranted to 
understand the clinical course and optimal management of this distinct entity.  
Keywords:  Cryptococcal meningitis, HIV; Diagnosis; Fungal Antigen; Aseptic Meningitis  
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Introduction 
Cryptococcal meningitis is the most common cause of meningitis in Sub-Saharan Africa and 
accounts for 15% of HIV/AIDS-related deaths globally [1-3]. Cryptococcal antigenemia, which 
precedes the development of cryptococcal meningitis, has a prevalence of 8.8% among HIV-infected 
Ugandan adult outpatients with CD4 T-cell counts <100 cells/μL, and this prevalence is two-fold 
greater among those hospitalized [4, 5]. Globally, the cryptococcal antigenemia prevalence is 
estimated at 6% in HIV infected individuals with CD4 T-cell counts <100 cells/μL [1].  
Current World Health Organization (WHO) guidelines recommend screening all antiretroviral 
therapy (ART) naïve HIV infected individuals with CD4 T-cell counts <100 cells/μL for 
cryptococcosis using a serum or plasma cryptococcal antigen (CrAg) test, followed by pre-emptive 
antifungal therapy if CrAg positive to diminish the risk of developing cryptococcal meningitis [6, 7]. 
If untreated, patients with cryptococcal antigenemia progress to develop meningitis symptoms within 
a median of 22 days (by latex agglutination) [8]. However, the exact timing of developing meningitis 
symptoms in individuals with a positive serum CrAg versus the ability to detect cryptococcal antigen 
in cerebrospinal fluid (CSF) remains unclear. The optimal treatment for this group of patients has not 
been defined. 
We characterized high-risk patients who were hospitalized with symptoms of meningitis 
including headache, neck pain, vomiting, and/or fever with a positive whole blood CrAg test, but with 
negative CSF evaluation (negative CrAg and no other bacterial, viral, mycobacterial or fungal 
etiology identified; hereafter referred to as ‘symptomatic antigenemia’ group). We compared this 
neurologic symptomatic antigenemia group to patients with confirmed CSF CrAg+ cryptococcal 
meningitis in terms of clinical presentation and hospital outcomes. 
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Methods 
Study Participants 
As part of screening for enrollment into the “Adjunctive sertraline for treatment of HIV-
associated cryptococcal meningitis” (ASTRO-CM) clinical trial (ClinicalTrials.gov: NCT01802385) 
[9], we prospectively consented 1,201 HIV-infected adults presenting with suspected meningitis to 
evaluate for the etiology of meningitis at Mulago National Referral Hospital and Mbarara Regional 
Referral Hospital in Uganda. Study participants were HIV-infected adults (≥18 years) with 
signs/symptoms of meningitis, who provided written informed consent for lumbar puncture, 
diagnostic testing, and collection of research data. We excluded individuals with past history of 
cryptococcal meningitis and females who were pregnant. Ethical approvals were obtained from the 
Uganda National Council of Science and Technology (UNCST), Mulago Hospital Research and 
Ethics Committee, and University of Minnesota.  
Study Procedures  
First, symptomatic hospitalized persons with suspected meningitis underwent finger stick 
testing of whole blood with the CrAg lateral flow assay (LFA) (Immy, Norman, Oklahoma, USA) 
[10]. Second, lumbar punctures were performed with CSF tested using CrAg LFA to establish a 
diagnosis of cryptococcal meningitis. All CrAg testing was independently repeated in the 
microbiology laboratory to confirm the point-of-care CrAg result. Tuberculous meningitis (TBM) was 
diagnosed by Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), mycobacterial growth indicator tube 
(MGIT) culture, or acid-fast bacilli smear [11].  Multiplex PCR (FilmArray Meningitis/Encephalitis 
Panel, BioFire Diagnostics, LLC, Salt Lake City, Utah) was also performed on a subset of samples to 
evaluate for potential viral and bacterial etiologies of meningitis [12]. Quantitative fungal cultures 
were performed on whole CSF, and plates were incubated at 30°C for 10 days on Sabouraud Dextrose 
Agar (SDA), as previously described [13, 14]. The overall stepwise diagnostic algorithm is presented 
in Supplemental Figure 1.  
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Statistical Analysis 
We analyzed data based on CSF CrAg test results. Individuals with first episode 
cryptococcosis were included in comparative analyses. We compared baseline characteristics and 
clinical outcomes of individuals in the symptomatic cryptococcal antigenemia group with the 
cryptococcal meningitis group. We compared continuous variables with Wilcoxon rank sum tests and 
compared categorical variables with Fisher’s exact tests. P-values <.05 were considered statistically 
significant. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). 
 
Results:   
Between August 2013 and May 2017, we consented 1,201 HIV-infected participants 
hospitalized with suspected meningitis for lumbar puncture. All participants first received a CrAg 
LFA test on finger stick whole blood. Of these, 60% (725/1201) had a positive blood CrAg test. Of 
those with a positive blood CrAg, 93% (671/725) had positive CSF CrAg and confirmed cryptococcal 
meningitis, and 7.4% (54/725) had negative CSF CrAg. Of the 574 participants with first episode of 
meningitis and a positive CSF CrAg, 0.9% (5/574) had cryptococcal meningitis and microbiologic-
confirmed TB meningitis co-infection (Figure 1). 
Among the 54 participants with negative CSF CrAg, 3 (6%) subsequently grew Cryptococcus 
on CSF culture (Range, 10 – 95 CFU/mL) with negative multiplex PCR, and two patients (13% of 15 
tested) had Cryptococcus DNA detected by multiplex PCR with sterile cultures (Table 1). Six 
participants (11%) were diagnosed with TBM using Xpert MTB/Rif (n=5), acid fast bacilli smear 
microscopy (n=1) and/or mycobacteria culture (n=3). There were no cases of viral or bacterial 
meningitis diagnosed among this group based on CSF profile, multiplex PCR, or bacterial culture. 
Thus, 43 were included in the final symptomatic antigenemia group for analysis. 
Participants in the symptomatic antigenemia group and the cryptococcal meningitis group had 
similar baseline characteristics (Table2. The CD4 T-cell counts in the symptomatic antigenemia 
group (median 29 cells/µL, IQR, 7-69) were not statistically different from the cryptococcal 
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meningitis group (median 16 cells/µL, IQR, 6-48; P=.16). Headache was a less common symptom in 
the symptomatic antigenemia group than the cryptococcal meningitis group, (84% versus 98%; 
P<.01).  The proportion of participants on antiretroviral therapy in the symptomatic antigenemia 
group did not differ from the cryptococcal meningitis group (53% versus 52%; P =.84). No participant 
initiated or changed antiretroviral therapy during hospitalization. A significantly higher proportion of 
participants in the symptomatic antigenemia group had normal CSF white blood cell counts (<5 
cells/µL) compared to the cryptococcal meningitis group (84% vs 64%; P<.01). Similarly, the median 
CSF opening pressure was 127 mmH2O (IQR 93-157) in the symptomatic antigenemia group 
compared to 270 mmH2O (IQR 180-400) in the cryptococcal meningitis group (P<.01). Among those 
in the symptomatic antigenemia group, 16% (5/32) had elevated CSF opening pressure >200 mmH2O.   
Of six symptomatic antigenemia participants with TB meningitis co-infection, CSF was more 
inflammatory compared to symptomatic antigenemia participants without TB meningitis. Participants 
with TB meningitis co-infection presented more frequently with abnormal CSF pleocytosis >5 white 
cells/µL (67% vs 16%, P =.02), however, the proportions presenting with elevated protein >45 mg/dL 
(60% vs 37%, P =.37), and opening pressure of >200 mmH2O (50% vs 16%, P =.33) were similar 
when compared to those with symptomatic antigenemia.   
Among the 96% (585/612) with known in-hospital outcomes, early mortality did not differ in 
the symptomatic antigenemia group 32% (11/34) who were treated with fluconazole monotherapy 
(initially 800mg/day) versus 31% (173/551) in the cryptococcal meningitis group who were treated 
with combination amphotericin B and fluconazole (P=.91). Among patients in the symptomatic 
antigenemia group, the median time to in-hospital death was 7 (IQR, 4 to 18 days, max, 31 days), and 
a further 21% had unknown outcome (e.g. fled from the hospital / lost to follow up). Thus, outcomes 
in this symptomatic antigenemia group, who generally appeared less ill at baseline, were suboptimal 
when receiving fluconazole monotherapy.  
 
Discussion:   
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We identified a group of HIV-infected individuals with cryptococcal antigenemia and 
symptomatic meningitis but without microbiologic evidence of CSF infection. We propose that these 
persons most likely have early cryptococcal meningitis. In the absence of testing blood for CrAg and 
only testing CSF, we would have missed their diagnosis. Likely these missed diagnoses commonly 
occur in immunocompromised populations throughout the world. These neurologic “symptomatic 
antigenemia” patients had relatively milder symptoms at baseline, normal CSF opening pressures, and 
slightly higher CD4 T cell counts, yet they still had 32% known early in-hospital mortality with the 
WHO and U.S. recommended fluconazole monotherapy for CrAg antigenemia.  While anecdotally 
recognized over the past ~4 decades, this is the first cohort describing this population and the 
prevalence (1 in 25 adults presenting with meningitis symptoms in Uganda). 
There are two important lessons from our findings.  First, diagnostic testing of 
immunocompromised individuals with suspected central nervous system (CNS) infection should 
always include blood testing of cryptococcal antigen, particularly in the absence of an identified CSF 
pathogen. Second, CNS cryptococcosis is a meningoencephalitis where early in infection, yeasts can 
be present in the brain parenchyma without CSF involvement. Untreated, eventually CSF involvement 
will occur based on the natural history of Cryptococcus neoformans. [8]. A South African autopsy 
study reported intra-parenchymal Cryptococcus in the brains of patients with cryptococcal 
antigenemia who received preemptive fluconazole therapy and later died [15].  
Second, the current guidelines recommending fluconazole therapy for isolated cryptococcal 
antigenemia are inadequate [7, 16, 17]. While these guidelines may be adequate for asymptomatic 
antigenemia, for persons with symptomatic CNS disease and no other identifiable cause of symptoms, 
patients should be approached similarly to CNS infection, with consideration of more aggressive 
management with amphotericin-based therapy or combination fluconazole and flucytosine. Of notable 
concern is the similar in-hospital mortality among these those with symptomatic antigenemia as 
compared with symptomatic cryptococcal meningitis patients.  Despite the fact that these 
symptomatic antigenemia patients were identified early during the continuum of cryptococcal disease 
while progressing to overt cryptococcal meningitis, we observed unacceptably high early mortality 
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(32%). The proximal cause of death was unclear, based on the available data. Even with preemptive 
fluconazole monotherapy in asymptomatic cryptococcal antigenemia persons screened in a multi-site 
cryptococcal screening and treatment program in Kampala Uganda, 28% were symptomatic at the 
time of clinic return [18]. Of these symptomatic cryptococcal antigenemia persons identified in 
outpatient clinics, 54% were dead or lost at 6 months [18]. Fluconazole monotherapy even at 
1200mg/day for CNS disease has been associated with a 68% mortality in a recent Ethiopian study 
[19].   
Therefore, given the implementation of national cryptococcal antigen screening programs 
where patients with symptomatic cryptococcal antigenemia will increasingly be identified, we posit 
that treating individuals with symptomatic cryptococcal antigenemia with a short course of 
amphotericin-based therapy could potentially improve their clinical outcomes. However, the dose and 
duration should be the subject of future research. We would also recommend an enhanced diagnostic 
approach, especially considering that 11% of those with symptomatic antigenemia had confirmed TB 
meningitis co-infection. A further proportion may have had TB meningitis missed on CSF testing, 
thus cryptococcal antigenemia alone still requires comprehensive diagnostic evaluation.  CSF culture 
detected Cryptococcus in 3 false negative CSF CrAg tests among 1201 (0.25%) CSF processed; all of 
whom had their cryptococcal infection detected by blood CrAg testing. In comparison, in the absence 
of blood CrAg testing, 4.2% (51/1201) would have not had their cryptococcal infection detected by 
standard CSF culture, CrAg testing, and microscopy.  Thus, we strongly recommend an enhanced 
diagnostic work up for all immunocompromised patients with suspected CNS infection to include 
blood cryptococcal antigen testing. 
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Figure 1: Study population: 1,201 individuals with suspected meningitis were screened with a blood 
CrAg test.  Overall, 40% (476/1,201) were CrAg negative in blood and excluded from this analysis; 
all whom were also CSF CrAg negative. Overall, 671 individuals were blood and CSF CrAg positive 
were diagnosed with cryptococcal meningitis.  Of 574 with first episode cryptococcal meningitis, 5 
had tuberculous meningitis co-infection and were excluded from this analysis. Of the 54 blood CrAg 
positive and CSF CrAg negative, 3 were later diagnosed by CSF culture and 2 by PCR with 
cryptococcal meningitis, 6 were diagnosed with microbiologically confirmed tuberculous meningitis 
(TBM), and 43 had neurologic symptomatic cryptococcal antigenemia.  
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TABLE 1: ALTERNATIVE DIAGNOSES 
  
 Diagnostic Testing 
Blood CrAg positive & 
CSF CrAg negative 
 (N=54) 
Blood & CSF CrAg 
positive 
(N=574) 
  
CSF CrAg positive on repeat testing 
in laboratory 
0 573 
CSF Cryptococcus culture positive 3 (6%) 500 (88%) 
CSF PCR performed 15 (28%) 86 (15%) 
Positive for Cryptococcus  2 (13%) 55 (64%) 
Positive for HHV6* 1 (7%) -- 
  Diagnosed with TBM 6 (11%) 5 (1%) 
Positive CSF AFB smear  1 of 47 0 of 14 
Positive CSF MTB culture 3 of 33 1 of 43 
Positive CSF Xpert MTB/Rif 5 of 48 4 of 46 
* additional PCR testing was negative for: Escherichia coli, Haemophilus influenzae, Listeria 
monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, 
cytomegalovirus (CMV), enterovirus, herpes simplex virus 1 and 2, human parechovirus, varicella 
zoster virus (VZV) 
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TABLE 2: BASELINE CHARACTERISTICS OF STUDY POPULATION 
Characteristics 
Neurologic Symptomatic 
Cryptococcal antigenemia group 
(n=43) 
Cryptococcal 
Meningitis group 
(n=569) 
P-value 
Men 44% (29%, 59%) 59% (55%, 63%) 0.06 
Age, years 38 (30, 45) 35 (29, 40) 0.13 
Receiving ART 53% (39%, 68%) 52% (48%, 56%) 0.84 
Fever 56% (41%, 71%) 49% (44%, 53%) 0.36 
Headache 84% (73%, 95%) 98% (96%, 99%) <0.01 
Photophobia 12% (2%, 21%) 27% (23%, 30%) 0.03 
Seizures 5% (0%, 11%) 14% (12%, 17%) 0.07 
Cough 21% (9%, 33%) 20% (17%, 24%) 0.91 
Abnormal Lung Exam 26% (13%, 39%) 15% (12%, 18%) 0.06 
Glasgow Coma Score < 15 48% (33%, 63%) 42% (38%, 46%) 0.47 
Hemoglobin, g/dL 10.6 (8.2, 11.9) 11.4 (9.9, 12.9) <.01 
CD4 T cells/L 29 (7, 69) 16 (6, 48) 0.16 
Creatinine, mg/dL 0.7 (0.2, 1.1) 0.7 (0.6, 0.9) 0.59 
CSF white cells <5 cells/L 84% (73%, 95%) 64% (60%, 68%) <0.01 
CSF protein, mg/dL 31 (22, 67) 43 (21, 94) 0.19 
CSF protein <45 mg/dL 63% (48%, 78%) 51% (47%, 56%) 0.15 
Opening Pressure, mmH2O 127 (93, 157) 270 (180, 400) <0.01 
Any abnormal: CSF white cells, 
Protein, or Opening Pressure 
44% (29%, 59%) 83% (80%, 86%) <0.01 
Proportions (95% confidence intervals) displayed are out of N with data in group; Median (IQR) 
displayed for continuous variables; P-values are from Wilcoxon Rank Sum tests for continuous 
variables, and Fisher's exact tests for categorical variables. Persons with TBM co-infection are 
excluded. 
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